Welcome to the new morningstar.co.uk! Learn more about the changes and how our new features help your investing success.

Hemogenyx Files New "Important" Patents For Antibodies Application

(Alliance News) - Hemogenyx Pharmaceuticals PLC said Friday it has filed a new patent for the ...

Alliance News 12 July, 2019 | 12:45PM
Email Form

(Alliance News) - Hemogenyx Pharmaceuticals PLC said Friday it has filed a new patent for the application of antibodies for bone marrow transplants in an "important development" for the biotechnology firm.

Hemogenyx explained the patent covers its CDX "method of application" of bi-specific antibodies for "conditioning patients for bone marrow transplantation."

The patent also covers the sequences of new monoclonal antibodies against a target proteins expressed in a number of types of leukaemia.

"Filing this patent is an important development and further solidifies Hemogenyx's leadership position in the development of new methods of bone marrow transplantation and treatments for blood cancers such as AML, acute lymphoblastic leukemia and possibly others," Chief Executive Vladislav Sandler said.

"The antibody we are developing, CDX, should, if successful, provide a new, effective and safe method of conditioning patients for bone marrow transplants, and has the potential to be a superior pharmaceutical for the treatment of blood cancers, for which survival rates are currently very poor," Sandler added.

Shares in Hemogenyx were 7.1% lower at 3.02 pence in London on Friday.

By Ahren Lester; ahrenlester@alliancenews.com

Copyright 2019 Alliance News Limited. All Rights Reserved.

Email Form

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Hemogenyx Pharmaceuticals PLC 1.91 GBX -6.83 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

Audience Confirmation

By clicking 'accept' I acknowledge that this website uses cookies and other technologies to tailor my experience and understand how I and other visitors use our site. See 'Cookie Consent' for more detail.

  • Other Morningstar Websites